Released May 16, 2022, before the open
10-Q filed May 16, 2022, 46 days after period end · 0001558370-22-008847
Q1 2022 · 10-Q
Revenue$16.09M$16.09M +42.1% vs Q1 2021+88.2% vs Q4 2021
Net Income-$2.29M-$2.29M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.05-$0.05 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$1,870,000N/M
Operating Cash Flow-$5,829,000N/M
Free Cash Flowderived-$6,058,000N/M
Margins · derived
Operating margin-11.6%+21.1 pt vs Q1 2021
Net margin-14.2%+34.2 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $16.09M | $11.32M | $21.65M | $10.44M |
| Net Income | -$2.29M | -$5.48M | $1.67M | -$7.26M |
| EPS Diluted | -$0.05 | -$0.14 | $0.10 | -$0.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR